70% 부분 간 절제술과 아세트아미노펜을 결합하여 급성 간 기능 부전의 쥐 모델 생성

Executive Industry Relevance

This rat model of acute liver failure combines 70% partial hepatectomy with acetaminophen dosing to create a reproducible system with a 48-hour therapeutic window, enabling evaluation of novel interventions before irreversible damage. The model addresses key limitations of existing ALF models by improving reproducibility and providing a platform to study combined physical and drug-induced liver injury mechanisms relevant to translational hepatology research.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in a clinically relevant ALF phenotype driven by combined surgical and chemical injury.
• Operational Value: Provides a standardized system for functional target validation through measurable biochemical and histological endpoints.
• Predictive Value: Supports predictive confidence by modeling human-relevant pathways of apoptosis, inflammation, and coagulation dysfunction.

Screening & Assay Development

• Assay Readiness: Generates quantifiable outputs including ALT, AST, ALP, PT, and INR for compound screening and dose-response analysis.
• Reproducibility: Demonstrates consistent ALF induction with up to 80% mortality within 24 hours of second acetaminophen dose, supporting assay standardization.
• <Scalability: Uses syngeneic hepatocyte transplantation to confirm reversibility, enabling recovery-based readouts for therapeutic screening.

Translational & Preclinical Research

• Disease Relevance: Recapitulates human ALF pathophysiology through elevated transaminases, impaired coagulation, and immune cell infiltration.
• Translational Continuity: Allows assessment of hepatocyte transplantation efficacy, linking discovery to cellular therapy development.
• Risk Mitigation: Provides a 48-hour window for intervention testing, reducing false negatives in preclinical efficacy studies.

Pipeline & Workflow Integration

The model fits within the discovery-to-preclinical continuum by providing a phenotypically defined system for target validation, assay development, and therapeutic screening in acute liver injury.

• Discovery Biology: Supports hypothesis testing of apoptosis and inflammation pathways through qPCR gene expression and histological analysis.
• Screening: Enables compound evaluation via serial biochemical measurements (ALT, AST, ALP) and survival endpoints.
• Analytics: Delivers quantitative dependent variables including enzyme levels, PT, INR, and survival rates for statistical comparison.
• Translational Research: Connects to preclinical validation through demonstrated reversibility via syngeneic hepatocyte transplantation.
• Enterprise Reuse: Establishes a reusable platform for iterative testing of therapeutic candidates across discovery and preclinical stages.

Operational & Enterprise Impact

• Scientific Value: Mechanistic de-risking through validated biomarkers of liver injury and regeneration.
• Operational Value: Standardized surgical and dosing protocol ensures reproducibility across laboratories and studies.
• Strategic Value: Improves go/no-go decisions by providing a time-bound window for therapeutic intervention assessment.
• Portfolio Impact: Enables risk-adjusted prioritization of candidates based on recovery of liver function and survival.

Implementation Considerations

• Requires microsurgical expertise for 70% partial hepatectomy and vascular ligation.
• Needs instrumentation for serum enzyme analysis, coagulation testing, and qPCR.
• Demands standardization of acetaminophen dosing and postoperative analgesia across study sites.
• Involves adaptation considerations for syngeneic hepatocyte isolation and transplantation procedures.
• Limited by rodent-to-human scaling in immune response and drug metabolism, per source material.

Biopharma FAQs